Erasca Lawsuit Deadline
Faruqi & Faruqi Reminds Erasca Investors of August 2026 Deadline in Securities Lawsuit
Anonymous
Erasca, Inc. (NASDAQ: ERAS) is facing a federal securities class action lawsuit after its stock crashed nearly 50% in a single day — wiping out roughly $2.8 billion in market value. Business Wire reports that investors have until **August 10, 2026** to apply to serve as lead plaintiff in the case.
The collapse was triggered on April 28, 2026, when shares fell from $21.49 to $9.90 in three business days. Two bombshells hit at once: a patent infringement letter from rival Revolution Medicines, and the death of a patient in Erasca's Phase 1 drug trial, according to Financial Content.
Two Shocking Disclosures Sent ERAS Stock Into Freefall
On April 27, 2026, Erasca filed a Form 8-K revealing it had received a legal letter from Revolution Medicines (RevMed). RevMed claimed that ERAS-0015 — Erasca's lead cancer drug — infringes on U.S. Patent No. 12,409,225. RevMed also alleged that Chinese scientists involved in developing the drug stole trade secrets, according to Rutland Herald.
Later that same evening, Erasca released early trial data showing a 62% response rate in lung cancer patients. But buried in the release was a patient death. A 66-year-old man with pancreatic cancer died from severe lung inflammation, known as Grade 3 pneumonitis. The dual blow sent the stock down 48.3% the next morning.
Lawsuit Alleges Erasca Misled Investors on Data and Patents
The class action lawsuit, filed in the Southern District of California, covers investors who bought ERAS shares between January 14, 2025 and April 27, 2026. It alleges that Erasca executives made false and misleading statements. Specifically, they touted preclinical data comparisons with RevMed's competing drug without disclosing that the data may have come from stolen trade secrets, according to Caledonian Record.
Law firm Faruqi & Faruqi, LLP is one of several firms investigating the case. Partner Josh Wilson urged investors with large losses to contact the firm. The lead plaintiff role goes to the investor with the biggest financial stake in the lawsuit. That investor will control how any settlement talks proceed, per Business Wire.
Erasca Calls Patent Claims Baseless, Analysts Stay Bullish
Erasca pushed back immediately. In its April 27 filing, the company said RevMed's infringement claims are "without merit" and that it plans to "contest the allegations vigorously." The drug was licensed from Joyo Pharmatech, a Chinese biotech firm whose scientists now sit at the center of the trade secret dispute.
Not everyone turned bearish. Analysts at J.P. Morgan kept an "Overweight" rating on the stock, arguing the selloff was "materially overdone." They called the patient death a "one-off case" tied to the patient's existing lung condition rather than a flaw in the drug itself. The biotech community remains divided on whether ERAS-0015 can survive both the legal and safety scrutiny.
What Comes Next for Erasca and Its Investors
The August 10, 2026 deadline is set by court order. After that date, a judge will name the lead plaintiff — typically the investor who lost the most money. That person or fund will then steer the lawsuit forward. If RevMed wins an injunction blocking ERAS-0015, Erasca could lose its only major drug asset, threatening the company's survival, per Weekly Voice.
The FDA may also step in. Regulators could pause Erasca's Phase 1 trial — called AURORAS-1 — to probe the pneumonitis death. Before the crash, ERAS had surged 700% in early 2026, drawing major institutional investors. One fund, Paradigm Biocapital Advisors, sold more than $44.5 million in shares just before the stock collapsed.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
5
Articles
4
Reach
5
Topics
A
AnonymousAuthor
